61 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
. Legacy Shire data from January 1, 2019 through March 31, 2019 assured by Apex Companies, LLC. See pages 105-109 for independent assurance reports. We … Methodology Environment, Health & Safety Performance Data UNGC Advanced Level CoP Reference Table GRI Standards Reference Table Independent Assurance Legal
6-K
TAK
Takeda Pharmaceutical Co
16 Jan 24
Current report (foreign)
6:01am
supply model. This initiative aligns with the reinforced quality assurance system for pharmaceutical products in the industry. We are committed to ensuring … , warehousing, manufacturing support, and quality assurance)
(5) Capital amount
1,676,345 million yen
50 million yen
(6) Date of foundation / incorporation
6-K
TAK
Takeda Pharmaceutical Co
31 May 22
Current report (foreign)
6:20am
import, local regulatory, development, quality assurance and commercial activities for SpikevaxTM from 1st August 2022
Companies concluded memorandum … , development, quality assurance and commercialization. Takeda will continue to provide distribution support under the current national vaccination campaign
6-K
EX-99.1
neze3
30 May 23
Current report (foreign)
6:11am
6-K
EX-99.1
cbcf9
23 Jun 23
Current report (foreign)
6:13am
424B5
z6apebs3db486ea07
25 Jun 20
Prospectus supplement for primary offering
6:14am
SC TO-T/A
n8v8 p6wx
11 May 18
Third party tender offer statement (amended)
4:43pm
424B2
kk9mx9s48xi6o
30 Jun 20
Prospectus for primary offering
7:24am
6-K
yaouiosgdgacrs3 t1u
27 May 20
Current report (foreign)
6:05am